UNSPSC 51183623: Insulin degludec

Insulin degludec is an ultra long-acting basal insulin analog used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.

UNSPSC 51183623 Insulin degludec is a Commodity code representing a specific pharmaceutical product, but the recent state and local solicitations tagged under this code show minimal direct procurement activity for the product itself. Instead, the opportunities reflect pharmaceutical distribution, management, and related services within health care and emergency medical contexts where insulin degludec may be one item among thousands in a broader medication portfolio.

State and local government procurement under this code encompasses pharmacy services for long-term care facilities, emergency medical services (EMS) pharmaceutical and supply distribution, group purchasing organization membership for hospital and clinic networks, and forensic laboratory reference materials—none of which specifically targets insulin degludec as a line item. Issuing bodies include county health departments (Dane County for long-term care pharmacy services), county medical centers (San Mateo Medical Center through group purchasing), municipal fire departments (City of Tucson EMS), behavioral health organizations (West Texas Centers), and county forensic laboratories (Pinellas County). Geographic activity spans Florida (Collier County, Seminole County, Pinellas County), Wisconsin (Dane County), Arizona (Tucson), Texas (West Texas Centers, Pinellas County), and California (San Mateo County). Two representative solicitations illustrate the scope: Dane County issued RFP 2026RFP061PR on September 30, 2026, requesting pharmaceutical services for Badger Prairie Health Care Center with responses due October 22, 2026, structured around comprehensive drug distribution, daily deliveries, and medication management compliant with state regulations; the City of Tucson Fire Department posted RFP 260217 on August 13, 2026, requesting BLS/ALS pharmaceuticals and supplies with vending-machine and software integration, responses due June 24, 2026, under federal funding (ARPA, HUD, FTA) with prevailing wage and DBE participation requirements. West Texas Centers for Mental Health and Mental Retardation solicited RFP RX1001 on August 10, 2026, for prescription pharmacy services across 23 counties serving over 7,000 individuals, with responses due August 21, 2026, emphasizing 48-hour turnaround for standard orders and integration with Streamline EHR. These procurements focus on distribution infrastructure, vendor capabilities, pricing models, and service delivery rather than procurement of insulin degludec specifically, indicating that the code's recent activity reflects state and local demand for pharmaceutical sourcing and management services within institutional and emergency medical settings rather than direct product line procurement.